Wall Street Slides as AI Stocks Tumble Following South Korea Tech Sell-Off 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Oil Prices Drop as Middle East Supply Recovery Eases Market Concerns 
South Korea’s KOSPI Rebounds as Samsung and SK Hynix Lead Tech Stock Recovery 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Gold Drops Below $4,000 as Strong US Dollar and Fed Rate Hike Expectations Pressure Bullion 
US Dollar Climbs to One-Year High as Fed Rate Hike Expectations Surge 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
South Korea Stocks Tumble as AI-Fueled Rally Faces Profit-Taking Pressure 
Bessent Says U.S. Must Strengthen Supply Chains and Economic Security 
Japan Manufacturing Growth Accelerates in June as Orders Surge Despite Iran War Cost Pressures 
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
